Segall Bryant & Hamill LLC Invests $8.23 Million in Boston Scientific Corporation (NYSE:BSX)

Segall Bryant & Hamill LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 81,620 shares of the medical equipment provider's stock, valued at approximately $8,234,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $1,762,522,000. Capital World Investors lifted its holdings in Boston Scientific by 28.7% in the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock valued at $2,492,041,000 after acquiring an additional 6,216,199 shares during the last quarter. Wellington Management Group LLP lifted its stake in Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after purchasing an additional 3,344,571 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Boston Scientific by 11,720.3% during the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after buying an additional 2,556,078 shares in the last quarter. Finally, Axiom Investors LLC DE grew its position in Boston Scientific by 208.2% in the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after buying an additional 2,535,007 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BSX shares. Truist Financial raised their price objective on Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Royal Bank Of Canada boosted their price objective on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Citigroup reissued a "buy" rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Finally, Barclays boosted their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Twenty-two research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $116.09.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president directly owned 18,705 shares in the company, valued at approximately $1,955,420.70. This trade represents a 19.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $106.97, for a total transaction of $5,348,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $19,077,243.74. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 461,970 shares of company stock valued at $47,755,193. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Down 0.9%

NYSE:BSX traded down $0.97 during trading hours on Friday, hitting $103.68. The stock had a trading volume of 8,571,099 shares, compared to its average volume of 6,759,200. The business's 50 day moving average is $103.40 and its 200-day moving average is $100.90. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. The company has a market cap of $153.39 billion, a price-to-earnings ratio of 75.68, a P/E/G ratio of 2.72 and a beta of 0.68. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $107.53.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm's revenue was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.56 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.